✦ LIBER ✦

Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies

✍ Scribed by Kapoor, Prashant; Fonseca, Rafael; Rajkumar, S. Vincent; Sinha, Shirshendu; Gertz, Morie A.; Stewart, A. Keith; Bergsagel, P. Leif; Lacy, Martha Q.; Dingli, David D.; Ketterling, Rhett P.

Book ID: 123602466
Publisher: Mayo Clinic
Year: 2010
Tongue: English
Weight: 827 KB
Volume: 85
Category: Article
ISSN: 0025-6196
DOI: 10.4065/mcp.2009.0677

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapeutic approaches for newly diagnos

Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs

✍ Fortunato Morabito; Massimo Gentile; Carla Mazzone; Sara Bringhen; Ernesto Vigna 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

Combined cytogenetic testing and fluores

Combined cytogenetic testing and fluorescence in situ hybridization analysis in the study of chronic lymphocytic leukemia and multiple myeloma

✍ Anne Wiktor; Daniel L. Van Dyke 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Molecular cytogenetic abnormalities in p

Molecular cytogenetic abnormalities in patients with concurrent chronic lymphocytic leukemia and multiple myeloma shown by interphase fluorescence in situ hybridization: evidence of distinct clonal origin

✍ Hong Chang; Ashutosh Wechalekar; Linda Li; Donna Reece 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Limited value of the international stagi

Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents

✍ Kuroda, Junya; Shimura, Yuji; Ohta, Kensuke; Tanaka, Hirokazu; Shibayama, Hirohi 📂 Article 📅 2014 🏛 Carden Jennings Publishing 🌐 English ⚖ 518 KB

Risk factors for, and reversibility of,

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

✍ Meletios A. Dimopoulos; Maria-Victoria Mateos; Paul G. Richardson; Rudolf Schlag 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

Circulating angiopoietin-1 to angiopoiet

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents

✍ Evangelos Terpos; Konstantinos Anargyrou; Eirini Katodritou; Efstathios Kastriti 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 456 KB 👁 1 views

## Abstract The circulating levels of several angiogenic cytokines [angiopoietin‐1 (Ang‐1), angiopoietin‐2 (Ang‐2), vascular endothelial growth factor (VEGF), angiogenin and basic fibroblast growth factor (bFGF)] were evaluated in 174 consecutive patients with newly diagnosed, symptomatic, multiple